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Abstract
OBJECTIVE: To introduce a clinical case from Pro-
fessor Huang Xi from Xiangya Hospital in tradition-
al Chinese medical (TCM) treatment for a major de-
pressive disorder (MDD) complicated by functional
dyspepsia (FD).
METHODS: A 26-year old unemployed male mi-
grant worker (Han nationality) presented himself at
the TCM outpatient department of our hospital on
May 13th 2013, with the chief complaint of persis-
tent low mood and negative emotions lasting 2.5
years. He was diagnosed as having MDD complicat-
ed by FD. The TCM differentiation made was "Gan-
qi-Yujie" (Liver-Qi stagnation). Zhiqiaochuanxiong
(ZQCX) decoction, composed of Zhiqiao (Fructus
Aurantii Submaturus) 40 g and Chuanxiong (Rhi-
zoma Chuanxiong) 40 g, was given to be taken
twice daily. The patient's condition was evaluated
with a 128-channel electroencephalogram (EEG)
and high-resolution manometry (HRM). During fol-
low-up the patient was monitored with the Patient
Health Questionnaire and Leeds Dyspepsia Ques-
tionnaire.
RESULTS: After treatment, the symptoms of depres-
sion and the FD comorbidity disappeared. Further-
more, the main EEG and HRM were significantly im-
proved after 1-7 weeks of ZQCX decoction adminis-
tration.
CONCLUSION: ZQCX decoction showed rapid pro-
kinetic and anti-depressive effects in a MDD pa-
tient complicated by FD. Most commonly used anti-
depressants target only the brain, whereas ZQCX
decoction targets the brain-gut axis according to
TCM theory.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Depression is a common cause of suicide and disability.
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Depression has complicated comorbidities, especially
functional gastrointestinal disorders (FGIDs).1,2 Pro-
spective studies have found a close relationship be-
tween depression and functional dyspepsia (FD).3 How-
ever, popular antidepressants, like selective serotonin
reuptake inhibitors (SSRIs), usually need several weeks
to take effect and have side-effects such as anorexia,
nausea, and vomiting, often leading to discontinuation
of the treatment. Patients must tolerate the adverse side
effects while undergoing a long therapeutic course with
a low response rate and delayed efficacy.1,4-6
The TCM pattern "Ganqi-Yujie" (GY) manifests as dis-
ordered mood and digestion, and has similar comorbid-
ities as depression and FD.5,7 The TCM anti-GY pre-
scription Chaihushugan San (CSS) exhibits prokinetic
and anti-depression, and has a long history of clinical
use.8-11 According to our clinical experience, the dosag-
es Zhiqiao (Fructus Aurantii Submaturus) and Chuanx-
iong (Rhizoma Chuanxiong) in the CSS prescription
should be increased for depression patients accompa-
nied with FD symptoms.5,7,12-14 Here, one illustrative
case of satisfactory therapeutic efficacy is reported.
CASE PRESENTATION
An unemployed male migrant worker, aged 26, present-
ed himself at the TCM outpatient department of our
hospital on May 13th, 2013 with the chief complaint
of persistent low mood and negative emotions. Two
and half years before, he had begun to feel depressed
because of unemployment and suffered from a lost ap-
petite. The patient then experienced epigastric fullness,
and belching for 15 months. He received CT scans
(Siemens, CT-Definition AS, Germany) of the head
and abdomen with no abnormal findings, and was di-
agnosed as having major depressive disorder complicat-
ed by FD in a local hospital. He had taken an antide-
pressant fluoxetine for 6 months. His mood was not
improved, but the digestive discomfort increased fol-
lowing a long course of treatment. Therefore, the pa-
tient stopped taking the medicine for 5 months before
coming to our hospital to receive TCM treatment.
METHODS
In our department, routine electroencephalogram
(EEG) examination and Patient Health Questionnaire
(PHQ-9) were used to evaluate the patients' condition
of depression, while high-resolution manometry (HRM)
and the Leeds Dyspepsia Questionnaire (LDQ) were
used to assess the FD symptoms. Informed consent was
obtained from the patient. EEG was performed using
the NeuroScan's SynAmps amplifier system (Neu-
roScan Inc, Herndon, VA, USA), which was connected
to a 128-channel EEG cap. The specific channels used
are shown in Figure 1. Gastrointestinal motility was de-
tected by the HRM system (Manoscan, Sierra Scientif-
ic Instruments, Los Angeles, CA, USA).
On May 14th, we checked his EEG, and found that
the electrical activity in his temporal lobe showed a sig-
nificant left-right asymmetry (T3-T4). There were ex-
cessive β waves in the T3 region and a few scattered
low-medium volatility θ waves (Figure 1A, 1B). His
PHQ-9 score was 20 for major depressive disorder, and
his LDQ score was 14 for functional dyspepsia (Figure
2). His HRM showed a low lower esophageal sphincter
pressure (LESP, -6.0 mm Hg compared with normal
4.8-32.0 mm Hg) (Figure 3A).
ZQCX decoction was composed of Zhiqiao (Fructus
Aurantii Submaturus), 40 g and Chuanxiong (Rhizoma
Chuanxiong), 40 g. The crude herbs (80 g) were decoct-
ed with 1.2 L water and concentrated to 400 mL.
ZQCX decoction was taken orally twice daily, 200 mL
each time. The entire treatment course lasted 8 weeks.
Quality control of ZQCX extracts is briefly described
in Figure 4 and Table 1.
RESULTS
One week after ZQCX treatment, the patient felt some
improvements in mood and appetite with reduced fre-
quency of early satiety and epigastric fullness. His EEG
showed a reduction in T3-T4 asymmetry with reducedβ waves in the T3 region (Figure 1C). The patient's
PHQ-9 score was 12.0; LESP was 4.3 mmHg; and
LDQ was 9.0 (Figure 2, 3B).
Three weeks after ZQCX treatment, the patient felt sig-
nificant improvements in mood with a willingness to
take part in conversation with others. His appetite was
almost regular, and the symptoms of early satiety, epi-
gastric fullness, and belching were much less frequent.
His EEG showed disappearance of T3-T4 asymmetry
and with no excessive β waves (Figure 1D). The pa-
tient's PHQ-9 score was 10.0; LESP was 11.8 mm Hg;
and LDQ was 6.0 (Figure 2, 3C).
Seven weeks after treatment, the patient was very satis-
fied with the treatment results. He said that his mood
was much more stable, and that he was more eager to
look for jobs. His FD symptoms were almost complete-
ly gone. His PHQ-9 score was 7.0 and LDQ was 2.0.
The therapeutic efficacy was fast and satisfactory (Fig-
ure 2). During the 6-month follow-up until December
18th, the results of the treatment satisfied the patient.
DISCUSSION
Major depressive disorder (MDD) is a refractory dis-
ease with unclear pathogenic mechanisms. It is a major
cause of suicide and disability.1,6 MDD with FGID co-
morbidities is as high as 93%.2 However, current anti-
depressants that fit into the "one-compound-one-tar-
get" paradigm are not effective at treating depression's
comorbidities.1,6,15 Fluoxetine targets only the brain to
treat depression; when depression is complicated by
functional dyspepsia, the drug's long administration
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may inhibit gut motility.16 Such a single-target anti-de-
pressive strategy often leads to discontinuation of treat-
ment, with no beneficial effects on the gut. SSRIs also
have obvious side effects and have a long lag period for
therapeutic effects.1 Therefore, it is necessary to explore
the potential that the TCM anti-"Ganqi-Yujie" therapy
may have for MDD complicated by FD.
We found that the depressive and indigestive symp-
toms in this patient's case almost disappeared follow-
ing ZQCX treatment compared with the conventional
dose used in the CSS prescription.5,7,9 These results
were strongly supported by improvements shown by
EEG and high-resolution manometry. The patient,
who had MDD complicated by FD, began to have sig-
nificant improvements in both the brain and gut symp-
toms after 1 week of ZQCX treatment.
In our recent studies, we found that the forced swim-
ming test may induce not only depressive disorder, but al-
so poor gastrointestinal mobility in rats.5,7,12 The ab-
sorbed bioactive compounds from Zhiqiao (Fructus
Aurantii Submaturus) and Chuanxiong (Rhizoma Ch-
uanxiong), such as ferulic acid and meranzin hydrate,
may exert antidepressive effects via the monoaminergic
mechanism and glutamic acid system, and can pro-
mote gastrointestinal mobility by up-regulation of the
brain-gut peptide ghrelin level.5,7,12-14 Interestingly, the
common pathogenetic and therapeutic mechanisms im-
Figure 1 EEG traces before and after ZQCX treatment
A: Specific channels used; B: EEG before ZQCX treatment; C: EEG after one-week ZQCX treatment; D: EEG after 3-week ZQCX treat-
ment. EEG: electroencephalography; ZQCX: Zhiqiaochuanxiong decoction.
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Figure 2 PHQ-9 and LDQ scores before and after ZQCX treat-
ment
PHQ-9: patient health questionnaire; LDQ: leeds dyspepsia
questionnaire; ZQCX: Zhiqiaochuanxiong decoction. Week
0: before treatment.
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Figure 3 Gastric motility during treatment
A: HRM detection before ZQCX treatment; B: HRM detection after 1-week ZQCX treatment; C: HRM detection after three-week
ZQCX treatment. HRM: high-resolution manometry; LESP: lower esophageal sphincter pressure; ZQCX: Zhiqiaochuanxiong decoc-
tion.
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plicated in depressive comorbidities did not occur until
the shared regulatory mediator alpha 2-adrenoceptor in
the brain-gut axis was regulated by meranzin hydrate
in the forced swimming rats.12 Therefore, we hypothe-
size that TCM antidepressants may exhibit prokinetic
and anti-depressive effects and simultaneously regulate
the depressed brain and the disordered gut during
stress .
The TCM antidepressant ZQCX decoction is different
from any currently available antidepressants because it
uses a "double-target" methodology rather than the
"one-compound-one-target" paradigm. Future anti-de-
pression strategies may account for limitations of "one-
compound-one-target," especially when facing chronic
and degenerative diseases. TCM holistic concepts may
provide inspiration for these future treatments.
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